Position in TRVI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
4 quarters on record
Derivatives in TRVI
reported options exposure · as of Mar 31, 2026CallValue
$4,294,800
CallShares
360,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Caption Management, LLC holds $195,300,170 across 69 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CGON |
CG Oncology, Inc.
|
378,480 | $25,615,526 | |
| 2 | IMCR |
Immunocore Holdings plc
|
661,786 | $19,952,847 | |
| 3 | CYTK |
Cytokinetics Inc
|
245,000 | $16,147,950 | |
| 4 | ELVN |
Enliven Therapeutics, Inc.
|
370,000 | $14,504,000 | |
| 5 | SLNO |
Soleno Therapeutics Inc
|
420,143 | $14,066,387 | |
| 6 | CNTA |
Centessa Pharmaceuticals plc
|
274,116 | $10,887,887 | |
| 7 | CORT |
Corcept Therapeutics Inc
|
260,000 | $10,480,600 | |
| 8 | HRMY |
Harmony Biosciences Holdings, Inc.
|
272,292 | $7,626,898 |
All Filings in TRVI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,294,800 | 360,000 | Call | Sole | 2026-05-15 | |
| 2025-09-30 | $640,500 | 70,000 | Put | Sole | 2025-11-14 | |
| 2025-09-30 | $219,600 | 24,000 | Call | Sole | 2025-11-14 | |
| 2025-06-30 | $820,500 | 150,000 | Put | Sole | 2025-08-14 | |
| 2025-06-30 | $2,010,772 | 367,600 | Call | Sole | 2025-08-14 | |
| 2025-03-31 | $7,069,960 | 1,124,000 | Call | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||